CRC patients treated with Oxaliplatin (OXA)-based chemotherapy showed miR-34a downregulation and TGF-β and SMAD4 overexpression, as well as in vitro experiments in OXA-resistant or not CRC cells by OXA treatment. The gene discussed is TGFB1; the disease is colorectal carcinoma.